Verified Nov 2026
Batteries & E-Mobility
·

Cambridge, Massachusetts
·
Since 2008
Agios Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2007 and employing 500 to 1,000 people. The company develops small-molecule drugs targeting rare diseases and cancer metabolism, with two approved oncology medicines: PYRUKYND for pyruvate kinase deficiency and AQVESME for thalassemia. Agios serves the medical and industrial equipment sectors through precision therapies.
Agios Pharmaceuticals at a glance
Revenue
$50-100M
Est. band
Employees
500-1,000
Founded
2008
Headquarters
Cambridge, Massachusetts
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Agios Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2007 and employing 500 to 1,000 people. The company develops small-molecule drugs targeting rare diseases and cancer metabolism, with two approved oncology medicines: PYRUKYND for pyruvate kinase deficiency and AQVESME for thalassemia. Agios serves the medical and industrial equipment sectors through precision therapies.
At a glance
Attribute | Detail |
|---|---|
Founded | 2008 |
Headquarters | Cambridge, Massachusetts |
Employees | 500-1,000 |
Revenue | $50-100M (estimated) |
Primary capability | Batteries & E-Mobility |
What Agios Pharmaceuticals makes
The company maintains a pipeline of investigational therapies targeting sickle cell disease and phenylketonuria alongside its two approved precision medicines.
Latest developments
2026-11-05 — Agios Reports Third Quarter 2026 Financial Results and Provides Business Update – Agios Pharmaceuticals, Inc. (agios.com)
2026-11-05 — Press Releases – Agios Pharmaceuticals, Inc. (agios.com)
2026-06-01 — Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib – Agios Pharmaceuticals, Inc. (agios.com)
2026-06-01 — Agios signs $165M pact for blood disorder drug that failed study (fiercebiotech.com)
2026-04-29 — Agios Reports First Quarter 2026 Financial Results and Provides Business Update – Agios Pharmaceuticals, Inc. (agios.com)
2026-02-12 — Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update – Agios Pharmaceuticals, Inc. (agios.com)
Company details
Agios is publicly traded on NASDAQ under ticker AGIO with a market capitalization of approximately $2.2 billion. Agios Pharmaceuticals was founded in 2008, has an estimated 500-1,000 employees, and is headquartered in Cambridge, Massachusetts.
Frequently asked questions
What does Agios Pharmaceuticals make?
Agios Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2007 and employing 500 to 1,000 people. The company develops small-molecule drugs targeting rare diseases and cancer metabolism, with two approved oncology medicines: PYRUKYND for pyruvate kinase deficiency and AQVESME for thalassemia. Agios serves the medical and industrial equipment sectors through precision therapies.
Where is Agios Pharmaceuticals headquartered?
Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts (88 Sidney Street, Cambridge, Massachusetts, 02139).
When was Agios Pharmaceuticals founded?
Agios Pharmaceuticals was founded in 2008.
How big is Agios Pharmaceuticals?
Agios Pharmaceuticals has an estimated 500-1,000 employees, with revenue in the $50-100M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
